New Data Presented at ESTRO 37 highlight the efficacy and safety of the BioProtect Balloon Implant® Spacer

April 24, 2018
Studies show the BioProtect biodegradable spacer provides significant reduction in rectal dose throughout the radiation treatment for prostate cancer, in IMRT, SBRT and Brachytherapy, while providing clinical advantages such as reproducibility and reliability. BioProtect Ltd. announced today that studies on the clinical use of the leading-edge BioProtect Balloon Implant® continue to demonstrate its benefits across different radiation modalities such as…
Read More

Meet us @ESTRO37 Barcelona Booth #4900

April 3, 2018
BioProtect will be exhibiting at #ESTRO 37 Meet us in booth #4900 Learn how radiation oncologists use balloon spacers to spare normal tissue in radiation oncology Get the latest about our blunt dissection procedure for superior safety To schedule a meeting email
Read More

BioProtect Launches an International Multi-Center Clinical Study Following FDA IDE approval

January 9, 2018
FDA has granted Investigational Device Exemption approval (IDE) to conduct a pivotal clinical study examining the use of the ProSpace™ Balloon System to prevent rectal toxicity following prostate cancer radiotherapy   TEL AVIV, Israel, January 9, 2018 /PRNewswire/ — BioProtect, the technology leader in biodegradable balloon spacers protecting normal tissue during radiation therapy, announced the launch of its clinical trial following Investigational…
Read More

BioProtect Establishes a New Subsidiary in Germany

January 10, 2018
BioProtect, Ltd, a leader in balloon spacers for radiation oncology , has established a new subsidiary in Germany called BioProtect GmbH, a company that is duly incorporated with offices located in the city of Hamburg This new subsidiary will help BioProtect expand in a large country that recently established a reimbursement code OPS-code 5-609-91 related to the spacer implantation procedure for…
Read More

IDE application approved by FDA

November 14, 2017
FDA has granted investigational Device Exemption approval (IDE) to conduct a pivotal clinical study Examining the Use of the ProSpaceTM balloon rectal spacer to prevent GI toxicity following prostate cancer radiotherapy. The company will soon start enrollment for its first large-scale international multi-center clinical study following FDA’s investigational Device Exemption (IDE).
Read More